Markets

Bruker Says B.I. Quant-Ur Module of Avance IVDR Provides Precise Results for Metabolite Qauntification in Urine

Bruker ( BRKR ) said Monday its new B.I. Quant-Ur module of its successful Avance in vitro diagnostics research (iVDr) now provides precise, sensitive and fully reproducible results for the quantification of metabolites in urine using Nuclear Magnetic Resonance ( NMR ).

Urine metabolic analysis is particularly valuable and information-rich, because the metabolic pathways of a wide range of nutrients, drugs and environmental contaminants can be identified in urine, even if urine is very complex to analyze, the company said in a press release.

B.I.Quant-Ur can quantify up to 150 metabolic compounds, including disease markers and non-targeted classification against healthy newborn models, opening new areas of research in frequent diseases such as diabetes, metabolic syndrome and obesity, the company said. Additionally, the tool can be used to investigate the role which nutrition and environmental conditions play in health, including functional food efficiency and drug dosage. The IVDr profiling modules B.I.Quant are for research use only and are not released for clinical diagnostics.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BRKR NMR

Other Topics

ETFs

Latest Markets Videos

    MTNewswires

    Founded in 1999, MT Newswires (formerly known as Midnight Trader) is a leading provider of original source, multi-asset class, real-time, global financial news and information to most of the largest banks, brokerage firms and professional market data, trading & research applications in North America.

    Learn More